Long-Term Outcomes Among Localized Prostate Cancer Survivors: Health-Related Quality-of-Life Changes After Radical Prostatectomy, External Radiation, and Brachytherapy

Miller, David C.; Sanda, Martin G.; Dunn, Rodney L.; Montie, James E.; Pimentel, Hector; Sandler, Howard M.; McLaughlin, William P.; Wei, John T.

doi:10.1200/jco.2005.07.116

Cited by 340 publications

(257 citation statements)

References 42 publications

Supporting

Mentioning

234

Contrasting

Unclassified

Order By: Relevance

“…Our findings extend the potential applications of a CArG inducible TNFbased gene therapy to patients' tumors where cytotoxins or radiation are either ineffective or poorly tolerated. For example, in prostate cancer, where radiotherapy and surgery are strongly associated with impotence, incontinence and rectal injury, 22 cytotoxic therapy via local infection with TNFerade and induction by resveratrol might offer an attractive alternative. More broadly, combining resveratrol with stable transduction of target tissues by CArG-dependent expression vectors might provide a practical answer to a current challenge for gene therapy.…”

Section: Resultsmentioning

confidence: 99%

Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy

et al. 2007

View full text Add to dashboard Cite

We report the anticarcinogenic, anti-aging polyphenol resveratrol activates the radio-and chemo-inducible cancer gene therapy vector Ad.Egr.TNF, a replication-deficient adenovirus that expresses human tumor necrosis factor a (TNF-a) under control of the Egr-1 promoter. Like ionizing radiation or chemotherapeutic agents previously shown to activate Ad.Egr.TNF, resveratrol also induces Egr-1 expression from its chromosomal locus with a possible role for Egr-1 promoter CC(A þ T)richGG sequences in the expression of TNF-a. Resveratrol induction of TNF-a in Ad.Egr.TNF-infected tumor xenografts demonstrated antitumor response in human and rat tumor models comparable to that of radio-or chemotherapy-induced TNF-a. Although sirtuins are known targets of resveratrol, in vitro inhibition of SIRT1 activity did not abrogate resveratrol induction of Egr-1 expression. This suggests that SIRT1 is not essential to mediate resveratrol induction of Egr-1. Nevertheless, control of transgene expression via resveratrol activation of Egr-1 may extend use of Ad.Egr.TNF to patients intolerant of radiation or cytotoxic therapy and offer a novel tool for development of other inducible gene therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…[6,11] The urinary irritative symptoms most commonly reported by patients after brachytherapy or radiotherapy include dysuria and frequency. [10] Changes in long-term urinary outcomes more than 1 year after brachytherapy are not well characterized as of yet, because sample size for later follow-up in these studies was low due to loss of follow-up. It should be noted that dysuria is not measured by the AUA-SI instrument, which has been used by some investigators to evaluate post-brachytherapy changes in urinary HRQOL.…”

Section: Impact Of Primary Prostate Cancer Treatment On Specific Hrqomentioning

confidence: 99%

“…The bowel/rectal problems are not as prevalent as is sexual dysfunction after prostate cancer treatment, but appear to have an overall impact (in terms of severity of bother) closer to that of the urinary HRQOL domain. [8,10] The onset of these symptoms occurs during or early after treatment, and can linger into later follow-up. A multivariable analysis of the HMS cohort suggested that bowel and rectal symptoms were less profound after brachytherapy than after external beam radiotherapy.…”

Section: Impact Of Primary Prostate Cancer Treatment On Specific Hrqomentioning

confidence: 99%

“…The original version of EPIC had 50 items, and retained the ability to discern function versus bother. In order to facilitate efficient questionnaire administration and optimize patient participation, an item-reduction analysis subsequently led to construction of the EPIC-26 short form [10] that retain the ability to measure outcomes in 5 HRQOL domains: urinary incontinence, urinary irritative/obstructive, bowel/rectal, sexual, and vitality/hormonal. Although EPIC-26 does not have the capacity to distinguish function from bother in the urinary or bowel domains, three bother items from the original UCLA-PCI (global urinary bother, global bowel bother, and overall sexual bother) are retained in both the longer EPIC-50 as well as in the EPIC-26 short form.…”

Section: Validated Questionnaires: Instruments To Measure Hrqolmentioning

confidence: 99%

See 1 more Smart Citation

Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer

Dandapani

Sanda

2008

Seminars in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

“…1,2 Radiation therapy is associated with similar QOL deficits, including sexual dysfunction, exacerbation of obstructive urinary symptoms, and bothersome bowel symptoms. [3][4][5] As a result, there has been long-standing interest in assessing quality-of-life outcomes among this patient population. However, prior efforts in this area have been primarily research oriented, focusing on instrument development, measurement and assessment of treatment-related consequences.…”

Section: Introductionmentioning

confidence: 99%

Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic

Gilbert

Dunn

Wittmann

et al. 2014

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Integrating quality-of-life (QOL) outcomes into clinics may assist providers in identifying and responding to problems experienced by cancer survivors. To date, however, patient-reported outcomes (PROs) such as QOL are used infrequently to guide care. We integrated QOL assessments into a prostate cancer survivorship clinic and compared recovery and satisfaction among men managed in the survivorship clinic with those followed with more routine care. METHODS: We conducted a before-after study comparing 235 men treated surgically for prostate cancer who received routine follow-up care with 102 men managed in a survivorship clinic characterized by point-of-care QOL reporting and integration of QOL scores (EPIC) following radical prostatectomy. We then assessed baseline and postprostatectomy QOL at 6 and 12 months, as well as patient satisfaction, and compared outcomes between groups. RESULTS: Although baseline QOL was comparable, scores were generally higher among the survivorship group at 6 months and 1 year compared with those followed with routine care. In particular, sexual function scores were significantly higher among patients managed in the survivorship clinic (52.2 vs 33.6 at 1 year, P <.01). Satisfaction scores were consistently higher in the survivorship clinic group compared with the routine-care group (all P <.05). CONCLUSIONS: Patient QOL and satisfaction were higher among men managed in a survivorship program, suggesting that disease-specific survivorship clinics that integrate QOL reporting into care pathways may yield better outcomes compared with less tailored approaches to patient care following cancer therapy. Cancer 2015;121:1484-91. V C 2014 American Cancer Society.KEYWORDS: prostate cancer, survivorship care, quality of life assessment. INTRODUCTIONAlthough most men treated for localized prostate cancer experience favorable cancer outcomes, treatment is often associated with lasting functional and quality-of-life (QOL) impairments. For example, men treated surgically (prostatectomy) face a 10%-15% risk of problematic urinary incontinence and greater than 50% risk of erectile dysfunction. 1,2 Radiation therapy is associated with similar QOL deficits, including sexual dysfunction, exacerbation of obstructive urinary symptoms, and bothersome bowel symptoms. 3-5 As a result, there has been long-standing interest in assessing quality-of-life outcomes among this patient population. However, prior efforts in this area have been primarily research oriented, focusing on instrument development, measurement and assessment of treatment-related consequences. Relatively little work has focused on integrating or translating QOL outcomes into clinical settings to guide patient care, in part because of a lack of available point-of-care tools to collect, score, and interpret patient-reported outcomes during clinic visits. Other barriers limiting the use of QOL in clinical care include logistical issues, such as lack of provider time to track functional outcomes or use them to guide interventions. As...

show abstract

Long-Term Outcomes Among Localized Prostate Cancer Survivors: Health-Related Quality-of-Life Changes After Radical Prostatectomy, External Radiation, and Brachytherapy

Cited by 340 publications

References 42 publications

Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy

Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy

Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer

Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic

Contact Info

Product

Resources

About